Vasoactive intestinal peptide (VIP): a new neuroendocrine marker of clinical progression in chronic heart failure?

Lucia P, Caiola S, Coppola A, Manetti LL, Maroccia E, Buongiorno AM, De Martinis C

Clinical endocrinology1 Dec 2003Cited by 6 (Europe PMC)

PMID14974913DOI10.1046/j.1365-2265.2003.01913.xPepBankPUB-14974913

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

No result from this study comes from a test of the peptide.

Natural levels measured5

These results measure the body's own peptide. Nobody was given the peptide. They are not evidence about taking it. They are left out of key results, evidence counts and charts.

01HumanEndogenous levelObservational studyOther
In patients with heart failure due to dilated cardiomyopathy, plasma VIP was higher than in healthy subjects.
In plain wordsIn people with heart failure, the body's own VIP in blood was higher than in healthy people.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
IncreasePlasma VIP in heart failure patients versus healthy subjects
Study
n = 52
Comparator
Healthy subjects
Outcome group
Heart function · Cardiovascular
Source sentences
Summary
higher in patients than in healthy subjects
1 context sentence(design, population, supporting numbers)
Summary · context
VIP was assayed in plasma within the first in-hospital day in 52 patients with heart failure due to dilated cardiomyopathy.
This result measures the body's own Vasoactive intestinal peptide (VIP, aviptadil). Nobody was given the peptide. It is not evidence about taking it.
Report a problemFND-1497491301
02HumanEndogenous levelObservational studyOther
Plasma VIP was higher than in healthy controls in elderly patients with heart failure but not in younger patients.
In plain wordsIn older people with heart failure, the body's own VIP in blood was higher than in healthy people. In younger patients it was not.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
MixedPlasma VIP in elderly versus younger patients compared with healthy controls
Study
n = 52
Comparator
Healthy controls
Outcome group
Heart function · Cardiovascular
Source sentences
Summary
higher in elderly but not in younger patients compared with healthy controls
1 context sentence(design, population, supporting numbers)
Summary · context
VIP was assayed in plasma within the first in-hospital day in 52 patients with heart failure due to dilated cardiomyopathy.
This result measures the body's own Vasoactive intestinal peptide (VIP, aviptadil). Nobody was given the peptide. It is not evidence about taking it.
Report a problemFND-1497491302
03HumanEndogenous levelObservational studyOther
In patients with heart failure, plasma VIP was inversely related to NYHA class: higher in NYHA 2 than in NYHA > 2 patients and in normal subjects.
In plain wordsIn people with heart failure, the body's own VIP in blood was lower in those with more severe disease.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
DecreasePlasma VIP and NYHA class
Study
n = 52
Comparator
Healthy subjects
Outcome group
Heart function · Cardiovascular
Source sentences
Summary
inversely related to NYHA class: higher in NYHA 2 than in NYHA > 2 patients and in normal subjects, in both young and elderly groups
1 context sentence(design, population, supporting numbers)
Summary · context
VIP was assayed in plasma within the first in-hospital day in 52 patients with heart failure due to dilated cardiomyopathy.
This result measures the body's own Vasoactive intestinal peptide (VIP, aviptadil). Nobody was given the peptide. It is not evidence about taking it.
Report a problemFND-1497491303
04HumanEndogenous levelObservational studyOther
In patients with heart failure, plasma VIP was not correlated with echocardiographic parameters.
In plain wordsIn people with heart failure, the body's own VIP in blood was not linked to heart ultrasound measures.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
No significant changePlasma VIP and echocardiographic parameters
Study
n = 52
Outcome group
Heart function · Cardiovascular
Source sentences
Summary
not correlated with echocardiographic parameters
1 context sentence(design, population, supporting numbers)
Summary · context
VIP was assayed in plasma within the first in-hospital day in 52 patients with heart failure due to dilated cardiomyopathy.
This result measures the body's own Vasoactive intestinal peptide (VIP, aviptadil). Nobody was given the peptide. It is not evidence about taking it.
Report a problemFND-1497491304
05HumanEndogenous levelObservational studyOther
In patients with heart failure, plasma VIP was not influenced by the aetiology of dilated cardiomyopathy.
In plain wordsIn people with heart failure, the body's own VIP in blood did not depend on the cause of the heart muscle disease.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
No significant changePlasma VIP and aetiology of dilated cardiomyopathy
Study
n = 52
Outcome group
Heart function · Cardiovascular
Source sentences
Summary
not influenced by the aetiology of dilated cardiomyopathy.
1 context sentence(design, population, supporting numbers)
Summary · context
VIP was assayed in plasma within the first in-hospital day in 52 patients with heart failure due to dilated cardiomyopathy.
This result measures the body's own Vasoactive intestinal peptide (VIP, aviptadil). Nobody was given the peptide. It is not evidence about taking it.
Report a problemFND-1497491305

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:58 UTC
Study results updated
Version 1
9 Oct 2026, 12:41 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.